SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Rainer Freynhagen, Michael Serpell, Birol Emir, Ed Whalen, Bruce Parsons, Andrew Clair, Mark Latymer, A Comprehensive Drug Safety Evaluation of Pregabalin in Peripheral Neuropathic Pain, Pain Practice, 2014, 14, 4
  2. 2
    Sieta T. Vries, Peter G. M. Mol, Dick Zeeuw, Flora M. Haaijer-Ruskamp, Petra Denig, Development and Initial Validation of a Patient-Reported Adverse Drug Event Questionnaire, Drug Safety, 2013, 36, 9, 765

    CrossRef

  3. 3
    Linda Härmark, Eugène Puijenbroek, Kees Grootheest, Intensive monitoring of duloxetine: results of a web-based intensive monitoring study, European Journal of Clinical Pharmacology, 2013, 69, 2, 209

    CrossRef

  4. 4
    Linda Härmark, Miguel Lie-Kwie, Lisette Berm, Han Gier, Kees Grootheest, Patients’ motives for participating in active post-marketing surveillance, Pharmacoepidemiology and Drug Safety, 2013, 22, 1
  5. 5
    Linda Härmark, Susanne Alberts, Eugène Puijenbroek, Petra Denig, Kees Grootheest, Representativeness of diabetes patients participating in a web-based adverse drug reaction monitoring system, Pharmacoepidemiology and Drug Safety, 2013, 22, 3
  6. 6
    Victoria R. Cornelius, Odile Sauzet, Stephen J.W. Evans, A Signal Detection Method to Detect Adverse Drug Reactions Using a Parametric Time-to-Event Model in Simulated Cohort Data, Drug Safety, 2012, 35, 7, 599

    CrossRef

  7. 7
    Linda Härmark, Kees van Grootheest, Web-based intensive monitoring: from passive to active drug surveillance, Expert Opinion on Drug Safety, 2012, 11, 1, 45

    CrossRef

  8. 8
    Eugène Puijenbroek, Kees Grootheest, Organization of Pharmacovigilance in the Netherlands,